Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06521801
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-22
Brief Title:
Cardio-Renal Registry
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Barts Health Cardio-Renal Registry
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BHCRR
Brief Summary:
Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease CKD Even after adjustment for known cardiovascular risk factors including diabetes and hypertension mortality risk progressively increases with worsening CKD As glomerular filtration rate GFR declines the probability of developing coronary artery disease CAD increases linearly and patients with GFR 60 mLmin173 m2 have 2-3-fold increased CV mortality risk relative to patients without CKD Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects Despite their high cardiovascular risk ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation This observation referred to as the treatment risk paradox has been well described and may be explained by physicians concerns regarding possible nonrenal side effects as well as renal toxicities Furthermore patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials Therefore recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population
This data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD It will also identify and characterise predictors of outcomes improve risk stratification and diagnostic evaluation
This data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD It will also identify and characterise predictors of outcomes improve risk stratification and diagnostic evaluation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None